Edwards Lifesciences Corp
Sentinellis Health Score
9.5/10
$47.3B
$6.1B
44.4x
AI Summary
Edwards Lifesciences makes medical devices to treat advanced heart diseases, focusing on transcatheter heart valve replacement (SAPIEN family), valve repair products (PASCAL, EVOQUE), and surgical structural heart solutions (INSPIRIS line) [Company Overview]. They sell through direct sales teams and distributors across the United States, Europe, Japan, and other international markets [Company Overview].
Edwards Lifesciences is a $47.3B medical device company specializing in advanced heart valve replacement and repair products, serving patients with serious cardiovascular diseases [Yahoo Finance]. The company has lagged the S&P 500 significantly over the past year (+7.8% vs. +26.6%), suggesting investor caution despite strong underlying financials [Yahoo Finance]. Recent insider selling activity and a JPMorgan Chase position reduction warrant attention [SEC Form 4] [EODHD].
Edwards is financially robust with excellent margins, zero net debt, and strong cash generation [Yahoo Finance].
Recent News
Are Wall Street Analysts Bullish on Edwards Lifesciences Stock?
Yahoo Finance· 2026-05-14
Risk Analysis
Opportunities
Full Financials
Executive Team
Unlock the full Edwards Lifesciences Corp analysis
Create a free account to access the complete AI-generated report with inline citations.
- Risks, opportunities, and red flags with sources
- 100+ financial metrics with charts and benchmarks
- Full news summaries with source links
- Executive team and compensation details
- PDF export for offline use
Other companies you might find interesting
Same sector (Healthcare) or comparable health.